Ovarian cancer: open trials in Canada

56 open trials have a site in Canada. Registry data; only the trial team decides who can take part.

NCT07546500
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Trial Treatment · Phase 3 · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Montreal · Montreal · Sherbrooke · Toronto · Toronto · Vancouver
Registry updated 2026-11-09
NCT04251052
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Trial Treatment · NRG Oncology
CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal · BCCA - Vancouver Cancer Centre, Vancouver
Registry updated 2026-11-06
NCT06787612
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Trial Treatment · Phase 2 · Regeneron Pharmaceuticals
Centre de Santé et de Services Sociaux de la Montérégie-Centre, Greenfield Park · Research Institute, McGill University Health Centre, Montreal · Jewish General Hospital, Montreal · Centre Hospitalier Universitaire (CHU) de Quebec - Universite Laval, Québec · Princess Margaret Cancer Centre, Toronto · CancerCare Manitoba, Winnipeg
Registry updated 2026-11-06
NCT07851025
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Trial Treatment · Phase 3 · AstraZeneca
Montreal · Toronto
Registry updated 2026-11-06
NCT04918186
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Trial Treatment · Phase 2 · Canadian Cancer Trials Group
BCCA - Kelowna, Kelowna · CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal · University Health Network, Toronto · Odette Cancer Centre, Toronto · BCCA - Vancouver, Vancouver
Registry updated 2026-11-05
NCT05879926
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Trial Treatment · Phase 3 · NRG Oncology
Royal Victoria Regional Health Centre, Barrie · Waterloo Regional Health Network, Kitchener · London Regional Cancer Program, London · CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal · Jewish General Hospital, Montreal · Oakville Trafalgar Memorial Hospital, Oakville · Lakeridge Health Oshawa, Oshawa · CHU de Quebec-Hopital du Saint-Sacrement (HSS), Québec · Allan Blair Cancer Centre, Regina · Saskatoon Cancer Centre, Saskatoon · Centre Hospitalier Universitaire de Sherbrooke-Fleurimont, Sherbrooke · Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto
Registry updated 2026-11-04
NCT06760819
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Treatment · Phase 2 · Bayer
Queen Elizabeth II Health Sciences Centre | Oncology, Halifax · Research Institute of the McGill University Health Centre | Women Health's Research Unit, Montreal · Princess Margaret Cancer Centre | Medical Oncology and Hematology, Toronto
Registry updated 2026-11-04
NCT07213804
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Trial Treatment · Phase 3 · Eli Lilly and Company
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton · Jewish General Hospital, Montreal · Centre intégré universitaire de santé et de services sociaux de l'Estrie Centre Hospitalier Universitaire -T, Sherbrooke · BC Cancer Surrey, Surrey · Sunnybrook Research Institute, Toronto · Princess Margaret Cancer Centre, Toronto
Registry updated 2026-11-04
NCT07694427
Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
Trial Treatment · Phase 3 · GlaxoSmithKline
Montreal · Toronto
Registry updated 2026-11-03
NCT06072781
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Trial Treatment · Phase 3 · Verastem, Inc.
McGill University Health Centre, Montreal · Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal · Princess Margaret Cancer Center, Toronto · British of Columbia, Vancouver
Registry updated 2026-11-02
NCT06843447
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC
Centre Hospitalier de l'Université de Montréal (Site 0102), Montreal · McGill University Health Centre (Site 0100), Montreal · Princess Margaret Cancer Centre (Site 0101), Toronto
Registry updated 2026-10-30
NCT07387263
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
Trial Treatment · Unity Health Toronto
Mount Sinai Hospital, Toronto · Sunnybrook Hospital, Toronto
Registry updated 2026-10-30
NCT06161025
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Trial Treatment · Phase 2/3 · Daiichi Sankyo
Arthur J. E. Child Comp CC, Calgary · London Health Sciences Centre (LHSC) - Victoria Hospital, London · McGill University Health Centre/Glen Site / Royal Victoria Hospital, Montreal · The Ottawa Hospital Cancer Centre, Ottawa · University Health Network - Princess Margaret Cancer Centre, Toronto
Registry updated 2026-10-26
NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Trial Treatment · Phase 2 · Daiichi Sankyo
Cross Cancer Institute, Edmonton · Sunnybrook Research Institute, Toronto · Princess Margaret Cancer Centre, Toronto · BC Cancer - Vancouver, Vancouver
Registry updated 2026-10-26
NCT07360314
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Trial Treatment · Phase 1 · EMD Serono Research & Development Institute, Inc.
Princess Margaret Cancer Centre, Toronto · BC Cancer - Vancouver - BC Cancer Agency, Vancouver
Registry updated 2026-10-20
NCT07816666
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Trial Treatment · Phase 3 · AstraZeneca
Abbotsford British Columbia · Montreal
Registry updated 2026-10-16
NCT07214779
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Trial Treatment · Phase 3 · Incyte Corporation
Tom Baker Cancer Center-Alberta Health Services (Ahs) - University of Calgary, Calgary · Cross Cancer Insititute, Edmonton · London Health Sciences Centre, London · Cedars Cancer Centre - McGill University Health Centre (Muhc) - Glen Site, Montreal · Sir Mortimer B Davis - Jewish General Hospital, Montreal · University Health Network UHN Princess Margaret Cancer Centre, Toronto
Registry updated 2026-10-15
NCT07286266
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Trial Treatment · Phase 3 · GlaxoSmithKline
Montreal · Toronto
Registry updated 2026-10-15
NCT05123482
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Trial Treatment · Phase 1/2 · AstraZeneca
Calgary · Montreal · Ottawa · Toronto · Vancouver
Registry updated 2026-10-13
NCT06824467
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Arthur J.E. Child Comprehensive Cancer Centre (Site 0512), Calgary · Health Sciences North Research Institute (Site 0517), Greater Sudbury · Trillium Health Partners - Credit Valley Hospital (Site 0508), Mississauga · CIUSSS de l'Est-de-l'Île-de-Montréal (Site 0505), Montreal · McGill University Health Centre (Site 0502), Montreal · Princess Margaret Cancer Centre (Site 0518), Toronto
Registry updated 2026-10-13
NCT07318558
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
CIUSSS - Saguenay-Lac-Saint-Jean (Site 0519), Chicoutimi · Centre Hospitalier de l'Université de Montréal (Site 0518), Montreal · McGill University Health Centre (Site 0516), Montreal
Registry updated 2026-10-13
NCT06726642
CfDNA in Hereditary And High-risk Malignancies 2
Research · University Health Network, Toronto
IWK Health Centre, Halifax · Jewish General Hospital, Montreal · Newfoundland and Labrador Health Services (previously Eastern Health), St. John's · Women's College Hospital, Toronto · Sinai Health System, Toronto · The Hospital for Sick Children, Toronto · University Health Network, Toronto · BC Cancer Agency, Vancouver
Registry updated 2026-10-08
NCT04429542
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Trial Treatment · Phase 1 · Bicara Therapeutics
Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal · Princess Margaret Cancer Centre, Toronto
Registry updated 2026-10-06
NCT05797168
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Trial Treatment · Phase 1/2 · AstraZeneca
Edmonton · London · Montreal · Toronto
Registry updated 2026-10-05
NCT07684612
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
Trial Treatment · Phase 3 · GlaxoSmithKline
Montreal · Toronto
Registry updated 2026-10-01

All Ovarian cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error